Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report

Aim: Classic activating mutations L858R and deletions in exon 19 (19del) in the gene for epidermal growth factor receptor (EGFR) are associated with sensitivity of the non-small cell lung cancer (NSCLC) to therapy with tyrosine kinase inhibitors (TKI). Insertions in EGFR exon 19 (19ins) are rare mut...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2017
Автори: Kozlov, V., Karpov, I., Kovalenko, S., Shamanin, V.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2017
Назва видання:Experimental Oncology
Теми:
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/137971
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report / V. Kozlov, I. Karpov, S. Kovalenko, V. Shamani // Experimental Oncology. — 2017 — Т. 39, № 2. — С. 155–156. — Бібліогр.: 7 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-137971
record_format dspace
spelling irk-123456789-1379712018-06-18T03:12:50Z Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report Kozlov, V. Karpov, I. Kovalenko, S. Shamanin, V. Case report Aim: Classic activating mutations L858R and deletions in exon 19 (19del) in the gene for epidermal growth factor receptor (EGFR) are associated with sensitivity of the non-small cell lung cancer (NSCLC) to therapy with tyrosine kinase inhibitors (TKI). Insertions in EGFR exon 19 (19ins) are rare mutations in NSCLC; response of cases with 19ins to TKI is not well studied. Here we report a case of NSCLC with 19ins in a Russian patient who was treated with gefitinib. We also overview cases of 19ins reported in the literature. Case description: A 48 years old female Russian patient was diagnosed with adenocarcinoma of the lung (T3N2M1, stage IV). Mutation 19ins was detected in the tumor biopsy by fragment analysis and genotyped by Sanger sequencing as p.I744_K745insKIPVAI. Treatment with gefitinib (250 mg/day) resulted in clinical and radiological improvements scored as partial response that lasted 12 months. Conclusion: Treatment with gefitinib of lung adenocarcinoma that carries mutation EGFR 19ins can result in durable response. 2017 Article Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report / V. Kozlov, I. Karpov, S. Kovalenko, V. Shamani // Experimental Oncology. — 2017 — Т. 39, № 2. — С. 155–156. — Бібліогр.: 7 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/137971 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Case report
Case report
spellingShingle Case report
Case report
Kozlov, V.
Karpov, I.
Kovalenko, S.
Shamanin, V.
Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report
Experimental Oncology
description Aim: Classic activating mutations L858R and deletions in exon 19 (19del) in the gene for epidermal growth factor receptor (EGFR) are associated with sensitivity of the non-small cell lung cancer (NSCLC) to therapy with tyrosine kinase inhibitors (TKI). Insertions in EGFR exon 19 (19ins) are rare mutations in NSCLC; response of cases with 19ins to TKI is not well studied. Here we report a case of NSCLC with 19ins in a Russian patient who was treated with gefitinib. We also overview cases of 19ins reported in the literature. Case description: A 48 years old female Russian patient was diagnosed with adenocarcinoma of the lung (T3N2M1, stage IV). Mutation 19ins was detected in the tumor biopsy by fragment analysis and genotyped by Sanger sequencing as p.I744_K745insKIPVAI. Treatment with gefitinib (250 mg/day) resulted in clinical and radiological improvements scored as partial response that lasted 12 months. Conclusion: Treatment with gefitinib of lung adenocarcinoma that carries mutation EGFR 19ins can result in durable response.
format Article
author Kozlov, V.
Karpov, I.
Kovalenko, S.
Shamanin, V.
author_facet Kozlov, V.
Karpov, I.
Kovalenko, S.
Shamanin, V.
author_sort Kozlov, V.
title Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report
title_short Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report
title_full Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report
title_fullStr Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report
title_full_unstemmed Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report
title_sort adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2017
topic_facet Case report
url http://dspace.nbuv.gov.ua/handle/123456789/137971
citation_txt Adenocarcinoma of the lung with rare insertion mutation in egfr exon 19 that had partial response to gefitinib: a case report / V. Kozlov, I. Karpov, S. Kovalenko, V. Shamani // Experimental Oncology. — 2017 — Т. 39, № 2. — С. 155–156. — Бібліогр.: 7 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT kozlovv adenocarcinomaofthelungwithrareinsertionmutationinegfrexon19thathadpartialresponsetogefitinibacasereport
AT karpovi adenocarcinomaofthelungwithrareinsertionmutationinegfrexon19thathadpartialresponsetogefitinibacasereport
AT kovalenkos adenocarcinomaofthelungwithrareinsertionmutationinegfrexon19thathadpartialresponsetogefitinibacasereport
AT shamaninv adenocarcinomaofthelungwithrareinsertionmutationinegfrexon19thathadpartialresponsetogefitinibacasereport
first_indexed 2023-10-18T21:16:59Z
last_indexed 2023-10-18T21:16:59Z
_version_ 1796152404032356352